Topics

FDA Approves Kalydeco as First and Only CFTR Modulator to Treat Eligible Infants with Cystic Fibrosis as Early as 6 Months

09:25 EDT 1 May 2019 | Speciality Pharma Journal

BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO® (ivacaftor) for use in children with cystic fibrosis (CF) ages six months to less than 12 months who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to KALYDECO based on clinical and/or in …

Original Article: FDA Approves Kalydeco as First and Only CFTR Modulator to Treat Eligible Infants with Cystic Fibrosis as Early as 6 Months

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Kalydeco as First and Only CFTR Modulator to Treat Eligible Infants with Cystic Fibrosis as Early as 6 Months"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...